Assoc Prof Tom Weickert with CATS study participant Leanne and research assistant Isabella Jacomb

CATS

RESEARCH STUDY

CANAKINUMAB ADD-ON TREATMENT FOR SCHIZOPHRENIA (CATS) STUDY

Canakinumab adjunctive treatment to reduce symptoms and improve cognition in people with schizophrenia displaying elevated blood inflammatory markers

HREC Approval Number: 14/072
What is the purpose of this study?

You are invited to participate in a research study of a human immune cell-line antibody on language, memory, and symptoms of schizophrenia. This human immune cell-line antibody, canakinumab, is a class of medication that decreases the levels of the protein interleukin-1beta (IL-1β). The IL-1β protein is produced in response to inflammation in your body and canakinumab can decrease IL-1β protein and inflammation by blocking the pathway. We hope to learn how this human immune cell-line antibody, in addition to your normal antipsychotic medication, can also improve thought processing and reduce symptoms in people with schizophrenia, and to determine if this human immune cell-line antibody can be used as a new therapeutic treatment for thinking problems and symptoms in people with schizophrenia.

What does the study involve?

The study involves a one-time injection of canakinumab or placebo and 6 monitoring assessment visits over a 4-month period. The assessments include:

  • An in-person screening interview
  • Cognitive tests
  • Symptom assessments
  • Medical examinations and clinical interviews
  • Blood collection
  • Structural and functional MRI
Who can enrol?

Men or women age 18-55 years old with a diagnosis of schizophrenia or schizoaffective disorder. You must be taking antipsychotic medication for at least one year but you must not be taking clozapine and have no other psychiatric diagnoses, history of seizures, substance abuse (within past 3 years), head injury or loss of consciousness, central nervous system infections or other serious or chronic infections, and if a woman, you cannot be pregnant.

Will I be reimbursed?

Your participation in this study may have associated expenses. Reimbursement will be provided for your time and for out-of-pocket expenses, such as travel to the centre.

Contact Information

If you have any questions, or if you are interested in participating, please feel free to contact a member of the research team:

Isabella Jacomb at 02 9399 1858, email: i.jacomb@neura.edu.au

Dr Thomas W Weickert at 02 9399 1730, fax: 02 9399 1034, email: t.weickert@neura.edu.au

See what’s going on at NeuRA

FEEL THE BUZZ IN THE AIR? US TOO.

‘Progressive. Incurable. Terminal. Nothing matters… I am going to die.’

‘There are days that I just cry like a baby. I’m meant to be the provider, the strong one. No son should have to change the underwear of their 57 year old father.’ Shin Liu is a man you want to know... kind, articulate and with love in his heart. At 57 years old however, Shin has planned his funeral. Two years ago, Shin was diagnosed with motor neurone disease (MND). Unlike many cancers or heart disease, there is not a single thing the medical profession can do to stop MND. This excruciating disease twists and contorts the human body in the most horrific way, and it quickly destroys the ability to move, speak, swallow and breathe. Life expectancy post diagnosis is 2.5 years. But NeuRA researchers are making exciting progress toward it's defeat. After years of meticulous research, we've learnt that in more than 90% of MND cases a protein called TDP-43 is responsible for the changes in motor neurones. In pre-clinical (non-human) trials, we have found that this protein can be controlled by a specially engineered peptide sequence (i.e. medication) which has the potential to stop MND in its tracks. But here is the most exciting development… we are observing improvements in movement, behaviour and memory upon administering this medication! This is innovative, ground-breaking research and we need your help to accelerate this research, which will in time enable clinical trials in people living with MND. Will you support or research today?
APPEAL